Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Cytek Biosciences, Inc.

Stage 2 · Advancing · week 6

As of Oct 22, 2026, Cytek Biosciences is in Stage 2, the uptrend phase, now in week 6 (since Sep 16, 2026). It closed at $5.43, 10.8% below its 52-week high and above its 200-day average, which is rising.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. More about the company

$5.43
-1.27% today
$706M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is CTKB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 14w
S4 15w
S4 21w
S1 14w
S2 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 3w → S4 14w → S1 6w → S2 7w → S3 5w → S4 15w → S1 3w → S4 12w → S1 5w → S2 7w → S3 4w → S4 21w → S1 14w → S2 14w → S3 12w → S2 1w → S1 1w → S4 10w → S1 7w → S2 5w current
Total tracked: 166 weeks across 20 stage runs.

CTKB among Medical Devices26th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…26CTKBStage 2 · wk 677−4.4%
vs 52W High
-10.8%
$3.36 lo$6.09 hi
10.8% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 6
1w13w26w
Week 6, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
17.0%
200 DMA: $4.64 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.57x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-4.4%
3M
+21.7%
6M
+27.5%
YTD
+10.4%
1Y
+30.2%
Scan Membership
Breakout Watch
Latest: 2024-12-17
3 appearances in last 60 days. First seen: 2022-09-12.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 6 · Vol 0.57x
2026-10-21S2
Wk 6 · Vol 0.77x
2026-10-20S2
Wk 5 · Vol 0.66x
2026-10-19S2
Wk 5 · Vol 0.57x
2026-10-16S2
Wk 5 · Vol 0.85x
2026-10-15S2
Wk 5 · Vol 0.73x
2026-10-14S2
Wk 5 · Vol 0.87x
2026-10-13S2
Wk 4 · Vol 1.17x
2026-10-12S2
Wk 4 · Vol 0.86x
2026-10-09S2
Wk 4 · Vol 3.40x
2026-10-08S2
Wk 4 · Vol 1.53x
2026-10-07S2
Wk 4 · Vol 1.62x
Moving averages & range
50 DMA
$5.12
200 DMA
$4.64
52W High
$6.09
52W Low
$3.36
5D Low
$5.25
Resistance levels (recent highs)
20d High
$6.09
60d High
$6.09
120d High
$6.09
250d High
$6.09
Next resistance
+12.2%
to 20d High
ROE
-23.0%
Profit margin -39.0%
Dividend Yield
0.00%
P/B 2.2

Cytek Biosciences: quick answers

What stage is Cytek Biosciences in?

As of Oct 22, 2026, Cytek Biosciences (CTKB) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 16, 2026 and is in week 6. What the four stages mean

Is Cytek Biosciences in an uptrend?

Yes. Cytek Biosciences is in a Stage 2 uptrend. It trades 17.0% above its 200-day average, which is rising.

How far is Cytek Biosciences from its 52-week high?

Cytek Biosciences closed at $5.43 on Oct 22, 2026, 10.8% below its 52-week high of $6.09. Its 52-week low is $3.36.

How has Cytek Biosciences performed over the past year?

As of Oct 22, 2026, Cytek Biosciences is up 30.2% over the past year and up 10.4% so far in 2026.

Which sector and industry is Cytek Biosciences in?

Cytek Biosciences is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.